Stocks · News reference

Galmed Pharmaceuticals Has Received A Notice Of Allowance For A U.S. Patent Titled "TREATMENT FOR FIBROSIS AND INHIBITION OF FIBROSIS"

Jul 1, 2026, 7:59 PMBenzinga Newsdesk

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Jul 1, 2026, 7:59 PM
Checked: Jul 1, 2026, 8:05 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaAug 19, 2026, 2:07 PMBenzinga Newsdesk
Galmed Pharmaceuticals shares are trading higher after the company's subsidiary Colospan announced the completion of a feasibility study supporting the development of a novel intraoperative colon tissue quality assessment platform.
GLMD
BenzingaAug 19, 2026, 12:55 PMBenzinga Newsdesk
Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
GLMD
BenzingaAug 19, 2026, 11:04 AMBenzinga Newsdesk
Galmed Pharma’s Subsidiary Colospan Completes Feasibility Study Supporting Development Of Intraoperative Colon Tissue Quality Assessment Platform
The prospective, single-arm study enrolled 32 colorectal cancer patients at three leading clinical centers in Israel. The primary objective was to demonstrate feasibility of intraoperative quantitative measurement of
GLMD
BenzingaAug 18, 2026, 11:50 PMBenzinga Newsdesk
Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
GLMD